Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 55Terminated 13Unknown 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 100Leukemia, Myeloid, Acute 79Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Myeloproliferative Disorders 40Leukemia, Myelogenous, Chronic, BCR-ABL Positive 37Leukemia, Myelomonocytic, Chronic 32Primary Myelofibrosis 30Lymphoma, Non-Hodgkin 30Polycythemia Vera 19Lymphoma 15Leukemia 15Hematologic Neoplasms 15Leukemia, Biphenotypic, Acute 14Thrombocythemia, Essential 13Multiple Myeloma 11Hodgkin Disease 11Histiocytosis, Langerhans-Cell 11Neoplasms 10Leukemia, Myeloid, Chronic-Phase 10Leukemia, Lymphocytic, Chronic, B-Cell 10Rhabdoid Tumor 9Neuroblastoma 9Medulloblastoma 9Glioma 9Ependymoma 9Anemia, Refractory, with Excess of Blasts 9Wilms Tumor 8Sarcoma 8Rhabdomyosarcoma 8Osteosarcoma 8

Interventions

Vorinostat 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Anemia, Refractory × Myeloid × Clear all
NCT00392353 2026-04-13

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
135 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡